Aa
Aa
A
A
A
Close
Avatar universal

HCC with new protocol of Immunotherapy

Does anyone know what are the success rates of multifocal HCC also in the liver portal , liver in good shape, Cirrhosis stage A, with systemic Immunotherapy? 
15 Responses
683231 tn?1467323017
Your doctor would be the most informed person to answer a question like that.

Have you had further testing CT or MRI?

Have you received this as a diagnosis?
683231 tn?1467323017
Your liver has cirrhosis by definition that is not considered good shape. You are still in relatively good health as you are still compensated that is a different thing from the health of your liver.
683231 tn?1467323017
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5464922/
683231 tn?1467323017
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5464922/
683231 tn?1467323017
https://radiopaedia.org/cases/multifocal-hepatocellular-carcinoma-with-portal-vein-thrombosis?lang=us
683231 tn?1467323017
The prognosis of HCC patients is much poorer in the presence of PVTT; their overall survival is only 2-4 months with supportive care [7–8]. The worse prognosis of HCC patients with PVTT may reflect several factors, including larger tumors, more numerous tumors, poorer tumor grade, worse liver function and higher serum levels of alpha-fetoprotein. These factors likely conspire to explain the low liver function, tumor aggressiveness, low chemotherapy tolerance and high risk of complications related to portal hypertension that are often observed in HCC patients with PVTT
683231 tn?1467323017
CONCLUSIONS

The available evidence suggests that hepatic resection may be appropriate first-line therapy for many HCC patients with Vp1-3 PVTT and preserved liver function, which would provide them access to a potentially curative treatment. In contrast, no curative treatment is currently available for HCC with Vp4 PVTT. Resection-based combination therapies may also be effective for many patients with HCC and PVTT, as long as preserved liver function is adequate. Future research is needed to optimize the type, dosing and timing of neoadjuvant or adjuvant treatments administered with hepatectomy in different HCC patients with PVTT. Future studies should focus on optimizing patient selection criteria for various combination therapies in order to maximize the benefits of resection. For patients with unresectable HCC and PVTT, then TACE/TAC, radiotherapy, or radioembolization with yttrium-90 should be considered. Future recommendations for managing HCC with PVTT must be based on clear evidence from large, well-designed, randomized controlled trials.
683231 tn?1467323017
Prognoses of patients with HCC and PVTT treated by hepatic resection
These results, together with systematic study of resection outcomes according to type of PVTT, argue for expanding official guidelines to recognize hepatic resection as a first-line option for selected patients with HCC and PVTT and preserved liver function. Analysis of 1021 patients in Japan with Vp3 or Vp4 PVTT who underwent resection showed a 5-year survival rate of 18.3%
683231 tn?1467323017
Average follow-up for all HCC patients in this study was 20.4 months. Overall median survival of all 389 patients was 11 months from the date of diagnosis. The 1-year survival rate was 49%, after 3 years 19% of all patients were still alive

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5016365/
683231 tn?1467323017
Immunotherapy for hepatocellular carcinoma: Current and future

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6603808/
683231 tn?1467323017
Is Immunotherapy for liver cancer successful?
At last year's Liver Meeting, researchers reported that people treated with this regimen had a median overall survival of 22.8 months. The 12-month overall survival rate was 61% and the 24-month survival rate was 48%. Treatment with Opdivo and Yervoy was generally safe, though side effects were common.Apr 1, 2020

https://www.cancerhealth.com/article/fda-approves-immunotherapy-combo-liver-cancer
683231 tn?1467323017
Systemic Treatment Options in Hepatocellular Carcinoma

https://www.karger.com/Article/FullText/499765
683231 tn?1467323017
Really good article citing different patient cases with differing amounts of liver disease.

From what I’m seeing is the preferred treatments for HCC if caught in early stages the preferred treatments are either removing the cancer tumors (resection) or liver transplant.

If the cancer is more advanced and operating is not an option that is when they will use immunotherapy type treatments to extend life this is referred to as palliative care while resection or transplant are considered curative.

https://aasldpubs.onlinelibrary.wiley.com/doi/10.1002/hep4.1481
683231 tn?1467323017
Bottom line if you define success of systemic immunotherapies as increased life span:

“For advanced HCC, median survival now surpasses 2 years with the recent approval of multiple systemic therapies. The results of several ongoing phase 3 trials are eagerly awaited for potential new first‐line systemic treatments. While more progress is needed to further improve patient survival, the prognosis and available treatment options for HCC are only anticipated to improve.“
683231 tn?1467323017
Hi Jack

Any news what is going on with your situation? I have my next CG scan 4/28 to see if my two growths have grown or exhibit other signs of HCC  
Have an Answer?

You are reading content posted in the Hepatitis C Community

Top Hepatitis Answerers
317787 tn?1473358451
DC
683231 tn?1467323017
Auburn, WA
Learn About Top Answerers
Didn't find the answer you were looking for?
Ask a question
Answer a few simple questions about your Hep C treatment journey.

Those who qualify may receive up to $100 for their time.
Explore More In Our Hep C Learning Center
image description
Learn about this treatable virus.
image description
Getting tested for this viral infection.
image description
3 key steps to getting on treatment.
image description
4 steps to getting on therapy.
image description
What you need to know about Hep C drugs.
image description
How the drugs might affect you.
image description
These tips may up your chances of a cure.
Popular Resources
For people with Obsessive-Compulsive Disorder (OCD), the COVID-19 pandemic can be particularly challenging.
A list of national and international resources and hotlines to help connect you to needed health and medical services.
Here’s how your baby’s growing in your body each week.
These common ADD/ADHD myths could already be hurting your child
This article will tell you more about strength training at home, giving you some options that require little to no equipment.
In You Can Prevent a Stroke, Dr. Joshua Yamamoto and Dr. Kristin Thomas help us understand what we can do to prevent a stroke.